Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.
Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Loman N, Malmström PO, Söderberg M, Walz TM, Fernö M, Hatschek T, Hedenfalk I; TEX study group. Kimbung S, et al. Among authors: lidbrink e. Clin Cancer Res. 2016 Jan 1;22(1):146-57. doi: 10.1158/1078-0432.CCR-15-0487. Epub 2015 Aug 14. Clin Cancer Res. 2016. PMID: 26276891
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.
Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, Lindström LS; TEX Trialists Group. Tobin NP, et al. Ann Oncol. 2015 Jan;26(1):81-88. doi: 10.1093/annonc/mdu498. Epub 2014 Oct 31. Ann Oncol. 2015. PMID: 25361981 Free PMC article. Clinical Trial.
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Hatschek T, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Söderberg M, Sundquist M, Walz TM, Hellström M, Svensson H, Aström G, Brandberg Y, Carstensen J, Fernö M, Bergh J. Hatschek T, et al. Among authors: lidbrink e. Breast Cancer Res Treat. 2012 Feb;131(3):939-47. doi: 10.1007/s10549-011-1880-9. Epub 2011 Nov 18. Breast Cancer Res Treat. 2012. PMID: 22094937 Clinical Trial.
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
Matikas A, Margolin S, Hellström M, Johansson H, Bengtsson NO, Karlsson L, Edlund P, Karlsson P, Lidbrink E, Linderholm B, Lindman H, Malmstrom P, Villman K, Foukakis T, Bergh J. Matikas A, et al. Among authors: lidbrink e. Breast Cancer Res Treat. 2018 Apr;168(2):349-355. doi: 10.1007/s10549-017-4599-4. Epub 2017 Nov 30. Breast Cancer Res Treat. 2018. PMID: 29190004 Free PMC article. Clinical Trial.
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
Margolin S, Bengtsson NO, Carlsson L, Edlund P, Hellstrøm M, Karlsson P, Lidbrink E, Linderholm B, Lindman H, Malmström P, Pettersson Skøld D, Søderberg M, Villman K, Bergh J; Scandinavian Breast Group Study SBG 2004-1. Margolin S, et al. Among authors: lidbrink e. Acta Oncol. 2011 Jan;50(1):35-41. doi: 10.3109/0284186X.2010.535847. Acta Oncol. 2011. PMID: 21174610 Clinical Trial.
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel.
Linderholm BK, Lidbrink E, Tallroth E, Einbeigi Z, Svensson H, von Wachenfeldt A, Norberg B, Carlsson L, Olsson ME, Bergh J, Wilking N, Hatschek T. Linderholm BK, et al. Among authors: lidbrink e. Breast. 2013 Dec;22(6):1142-7. doi: 10.1016/j.breast.2013.07.041. Epub 2013 Aug 20. Breast. 2013. PMID: 23968864 Free article. Clinical Trial.
Dietary habits and prognostic factors in breast cancer.
Holm LE, Callmer E, Hjalmar ML, Lidbrink E, Nilsson B, Skoog L. Holm LE, et al. Among authors: lidbrink e. J Natl Cancer Inst. 1989 Aug 16;81(16):1218-23. doi: 10.1093/jnci/81.16.1218. J Natl Cancer Inst. 1989. PMID: 2547078
49 results